Coste del tratamiento del cáncer de mama por estadío clínico en el País Vasco

Arrospide, Arantzazu; Soto-Gordoa, Myriam; Acaiturri, Teresa; López-Vivanco, G.; Abecia, Luis Carlos; Mar, Javier

doi:10.4321/s1135-57272015000100010

Cited by 15 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All cancer patients. Age 60–69 [ 22 ] Mean (SD) Functional scales Global health status/QoL M 98 34.2 20.4 61.8 (24.4) F 49 35.2 25.1 Physical function M 98 50 26.5 0.021 76.3 (23.5) F 49 39 28.2 Role function M 98 34.4 30.1 72.6 (32.7) F 49 26.9 27.6 Emotional function M 98 61.5 25.8 0.026 71.8 (24.3) F 49 51.7 23.3 Cognitive function M 98 67.7 27.3 83.1 (21.6) F …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study

Hernández

Jiménez-López²,

Sanz-Yagüe³

et al. 2018

Pain Ther

View full text Add to dashboard Cite

IntroductionBreakthrough pain (BTP) has great repercussions on the quality of life, and on the use of health resources. The scope of BTP costs in cancer patients is unknown. The purpose of this study was to evaluate the economic cost of BTP in patients with cancer and the relationship with their quality of life.MethodsA 1-month observational prospective cost-of-illness study was designed. The patients recorded the consumption of health resources and drugs related to BTP in a diary. The current symptoms in Edmonton Symptoms Assessment Scale (ESAS) and their quality of life (EORTC QLQ-C30, version 3) were assessed. The direct medical and non-medical costs fixed and variable and the indirect costs of the patient and the caregivers were evaluated. Factors related to cost and quality of life were identified using linear generalized models (LGM) type gamma and logistic link. Participants were oncologic patients with BTP, older than 18 years, with controlled basal pain.ResultsEight Spanish pain units, eight palliative care units, and one oncology department included 152 patients. One hundred patients (65.8%) were male and the mean age was 66.8 years (95% CI 64.8–68.8). The total cost per patient was 2941.60 euros per month: 88% direct medical costs, 5% non-medical direct costs, and 7% indirect costs due to lost productivity. A better score in EORTC QLQ-30 quality of life was associated with a reduction in overall costs.ConclusionsThe study showed the results of the first real-life prospective study evaluating the cost of illness of BTP in cancer patients demonstrating that the presence of breakthrough pain in a cancer patient causes a very significant increase in healthcare costs.FundingKyowa Kirin Farmacéutica, S.L.U.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Sample size was calculated based on one study on patients with breast cancer where the monthly costs on the metastatic cancer was 1489 euros. For a standard deviation of 250 euros and a 95% confidence interval and a precision of 41.68 euros, it was estimated that a sample of 140 patients yield a power of 80% [ 22 ].…”

Section: Methodsmentioning

confidence: 99%

Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study

Hernández

Jiménez-López²,

Sanz-Yagüe³

et al. 2018

Pain Ther

View full text Add to dashboard Cite

show abstract

“…In one study on patients with breast cancer, monthly cost was estimated at 1489euros. For a standard deviation of 250euros, a 95% confi dence interval and a precision of 41.68euros, it was estimated that a sample of 140 patients yield a power of 80% [22]. Data detailed in this manuscript refers to the analysis of clinical evolution of the patients in the same sample for what the sample size was appropriate.…”

Section: Sample Size Calculationmentioning

confidence: 99%

Assessment of symptoms, quality of life and associated costs in a one-month follow-up of cancer patients with breakthrough pain: The IMDI Study

Pérez¹,

Jiménez-López²,

Sanz-Yagüe³

et al. 2020

Open J Pain Med

View full text Add to dashboard Cite

Purpose: Breakthrough Pain (BTP) observed in up to 66% of cancer patients, is more common in patients with advanced cancer stages and is usually associated with a poor prognosis. The objective of this study was to evaluate the quality of life and control of associated symptoms of cancer patients with breakthrough pain (BTP) after a one-month follow-up in pain and palliative care units and measure the associated cost savings after our intervention. Methods/patients: A one-month observational prospective study was designed. Eight Spanish pain units, eight palliative care units, and one oncology department participated. On baseline and one-month visit, the Edmonton Symptoms Assessment Scale (ESAS), Brief Pain Inventory (BPI) and the quality of life (EORTC QLQ-C30, version 3) were assessed. The direct medical and non-medical costs fi xed and variable and the indirect costs of the patient and the caregivers were evaluated and published previously. Factors related to cost and quality of life, were identifi ed using Linear Generalized Models (LGM) type gamma and logistic link. Participants were oncologic patients with BTP, older than 18 years, with controlled background pain. Results: A total of 152 patients with a mean age of 66.8 years (95% CI 64.8-68.8), and 65.8% males were included. All symptoms (ESAS) were signifi cantly improved (p<0.05) from baseline to one month of follow-up. BPI dimensions and all functional and symptoms dimensions of EORTC QLQ-30 were also improved in one month (p<0.01). An improvement in EORTC QLQ-30 global health status-quality of life was associated with a reduction in overall BTP costs. Conclusions: Cancer patients improved their quality of life and cancer associated symptoms in only one month of treatment in pain and palliative care units, and this improvement leads to signifi cant BTP cost savings.

show abstract

“…A study conducted in Spain described the economic consequences of implementing new clinical practice guidelines 7 based on the medical records of individual patients. Research related to cancer costs based on the condition of cancer patients including clinical stage, associated with variables from administrative and clinical databases, is still not widely done, both in Spain and other countries.…”

Section: Introductionmentioning

confidence: 99%

“…Based on the new cases in women of all ages in 2020, the highest was breast cancer with 65,858 cases (30.8%); meanwhile, in men of all ages, the highest number of new cancer cases was lung cancer with 25,943 cases (14.1%). 6 A study conducted in Spain described the economic consequences of implementing new clinical practice guidelines 7 based on the medical records of individual patients. Research related to cancer costs based on the condition of cancer patients including clinical stage, associated with variables from administrative and clinical databases, is still not widely done, both in Spain and other countries.…”

mentioning

confidence: 99%

Breast, Cervical, and Lung Cancer: A comparison of Real Healthcare Costs and INA-CBGs Rates in the Era of National Health Insurance

et al. 2023

View full text Add to dashboard Cite

Background: In Indonesia, the cost of cancer treatment has been determined by the Indonesian Case Base Groups (INA-CBGs) based on a code called the INA-CBG's rates. However, a fair claim should be based on the severity of the disease and the class of treatment in the hospital, not on the rates of code. In fact, the real cost of therapy for cancer is influenced by several factors including stage, comorbidity, and severity (INA-CBGs coding, type of hospital, hospital class, treatment grade, side effects, and length of stay), so in many cases, there are reported differences between the real costs and the INA-CBGs rates charged to patients. Objective: This study aims to investigate the difference between real treatment costs and INA-CBG's rates for cases of lung cancer, cervical cancer, and breast cancer at a cancer center hospital in Indonesia. Methods: This work uses an observational study, and the data were taken retrospectively from hospital financial data and patient medical records. The data were then analyzed using a one-sample t-test to determine the difference between real costs and INA-CBGs costs. Results: The results showed that there was no significant difference between real costs and INA-CBG's cost on stage II lung cancer treatment in grade 2 with a sig. value of 0.683; code C-4-13-II in grade 3 with a sig. value of 0.151; and code C-4-13-III in grade 3 with a sig. value of 0.650; where the significance level (t alpha) is more than 0.05. Furthermore, the treatment costs for cervical cancer with codes C-4-13-I and C-4-13-II in grade 1 had sig. values of 0.155 and 0.720 respectively. Lastly, the treatment cost for breast cancer patients with codes C-4-12-II in grade 3 had a sig. value of 0.145 and code C-4-13-II in grade 3 showed a sig. value of 0.091. Conclusion: Although statistical evaluation showed a significant difference for some cases and not significant for other cases, in real conditions, there is a difference between the INA-CBGs and the real costs that must be evaluated by the government and stakeholders to provide justice for cancer patients.

show abstract

Coste del tratamiento del cáncer de mama por estadío clínico en el País Vasco

Cited by 15 publications

References 11 publications

Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study

Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study

Assessment of symptoms, quality of life and associated costs in a one-month follow-up of cancer patients with breakthrough pain: The IMDI Study

Breast, Cervical, and Lung Cancer: A comparison of Real Healthcare Costs and INA-CBGs Rates in the Era of National Health Insurance

Contact Info

Product

Resources

About